Skip to main content
. Author manuscript; available in PMC: 2017 Jan 24.
Published in final edited form as: Biomaterials. 2014 May 13;35(24):6454–6461. doi: 10.1016/j.biomaterials.2014.04.014

Figure 3.

Figure 3

(a) Protein-oligonucleotide conjugation is required for effective intracellular delivery of HRP by C14-113 LNPs. HeLa cells were treated as indicated for 3 h (500 ng HRP/well) and then subjected to an HRP activity assay (mean ± SD, n = 4). *** indicates p < 0.001 comparing LNP + HRP-DNA treatment to all other control treatments. (b) Following treatment of HeLa cells with C14-113 LNPs encapsulating HRP-oligo conjugates, immunocytochemical staining and confocal fluorescence microscopy confirmed intracellular HRP localization. Cells were treated in 6-well plates for 3 h with an LNP dose corresponding to 10 µg of HRP per well. Blue: nuclei; green: membrane; purple: F-actin; red: HRP.